EWA
CNTA

Evolution Wealth Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Evolution Wealth Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-160
Closed -$3K – 253
2021
Q3 		$3K Buy
+160
New +$3.31K ﹤0.01% 597

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Evolution Wealth Advisors's CNTA Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q4 2021, closing a stake of 160 shares — an estimated $3K sold.

Evolution Wealth Advisors first reported a position in CNTA in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 47 funds tracked by Wall St. Rank hold CNTA as of Q4 2021.

  • Evolution Wealth Advisors reported no remaining Centessa Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Evolution Wealth Advisors sold 160 Centessa Pharmaceuticals shares in Q4 2021, an estimated $3K.
  • Evolution Wealth Advisors first reported a position in Centessa Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Evolution Wealth Advisors's Centessa Pharmaceuticals position peaked at $3K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.